Evidence map›Paper›PMID 27931134›Full record

ArticleLeukemia & lymphoma2017

Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies.

Davis M Seelig, Daisuke Ito, Colleen L Forster, Una A Yoon, Matthew Breen, Linda J Burns, Veronika Bachanova, Kerstin Lindblad-Toh, Timothy D O'Brien, Stephen C Schmechel and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Hypermethylation-Mediated Silencing ofInternational journal of molecular sciences · 2022
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Davis M Seeliga Department of Veterinary Clinical Sciences, College of Veterinary Medicine , University of Minnesota , St. Paul , MN , USA.
Daisuke Itoa Department of Veterinary Clinical Sciences, College of Veterinary Medicine , University of Minnesota , St. Paul , MN , USA.
Colleen L Forsterc The University of Minnesota Biological Materials Procurement Network (BioNet), University of Minnesota , Minneapolis , MN , USA.
Una A Yoona Department of Veterinary Clinical Sciences, College of Veterinary Medicine , University of Minnesota , St. Paul , MN , USA.
Matthew Breend Department of Molecular Biomedical Sciences, College of Veterinary Medicine , Center for Comparative Medicine and Translational Research, North Carolina State University , Raleigh , NC , USA.
Linda J Burnsb Masonic Cancer Center , University of Minnesota , Minneapolis , MN , USA.
Veronika Bachanovab Masonic Cancer Center , University of Minnesota , Minneapolis , MN , USA.
Kerstin Lindblad-Tohg Broad Institute of MIT and Harvard , Cambridge , MA , USA.
Timothy D O'Brieni Department of Veterinary Population Medicine, College of Veterinary Medicine , University of Minnesota , St. Paul , MN , USA.
Stephen C Schmechelk Department of Pathology , University of Washington , Seattle , WA , USA.
Anthony E Rizzardik Department of Pathology , University of Washington , Seattle , WA , USA.
Jaime F Modianoa Department of Veterinary Clinical Sciences, College of Veterinary Medicine , University of Minnesota , St. Paul , MN , USA.
Michael A Lindenb Masonic Cancer Center , University of Minnesota , Minneapolis , MN , USA.
University of Minnesota · USUniversity of Minnesota Medical Center · USUniversity of Washington · USBroad Institute · USUNC Lineberger Comprehensive Cancer Center

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)KL2TR000113 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$5.4M
NCATS NIH HHS KL2 TR000113NCATS NIH HHS UL1 TR000114NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

Activation of the classical nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway is a common molecular event observed in both human and canine diffuse large B-cell lymphoma (DLBCL). Although the oncogenic potential of the alternative NFκB pathway (ANFκBP) has also been recently identified in DLBCL, its precise role in tumor pathogenesis and potential as a treatment target is understudied. We hypothesized that up-regulation of the ANFκBP plays an important role in the proliferation and survival of canine DLBCL cells, and we demonstrate that the ANFκBP is constitutively active in primary canine DLBCL samples and a cell line (CLBL1). We further demonstrate that a small interfering RNA inhibits the activation of the NFκB pathway and induces apoptosis in canine DLBCL cells. In conclusion, the ANFκBP facilitates survival of canine DLBCL cells, and thus, dogs with spontaneous DLBCL can provide a useful large animal model to study therapies targeting the ANFκBP.

Indexed as

Signal TransductionAnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalDisease Models, AnimalDogsGene ExpressionGenes, ReporterHumansLymphoma, Large B-Cell, DiffuseMolecular Targeted TherapyNF-kappa BAntineoplastic AgentsNF-kappa Balternative NFκB pathwaycanine modelcomparative pathologyDiffuse large B-cell lymphomatargeting therapy

Identifiers

PMID27931134
PMCPMC6198319
OpenAlexW2560576566

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.